# Galaxy Yuanhui Investment

> Galaxy Yuanhui Investment is a VC fund backing Industrial and Health Diagnostics. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 9
- Last investment: Apr 2026
- Lead investor: 0%
- Last updated: Aug 2026
- Website: https://www.chinastock.com.cn/yhwz/yhyhtz/index.html

Galaxy Yuanhui Investment is a VC fund focused on Industrial and Health Diagnostics. Galaxy Yuanhui Investment engages in alternative investment business.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Industrial | 2 | 22% |
| Health Diagnostics | 2 | 22% |
| Industrial Manufacturing | 2 | 22% |
| Retail | 1 | 11% |
| Medical | 1 | 11% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 3 | 33% |
| Series A | 2 | 22% |
| Series B | 2 | 22% |
| Series E | 1 | 11% |
| Venture - Series Unknown | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Link Touch | Link Touch specializes in the research, development, and production of force sensors and force control products. It has deep experience accumulation and technical advantages in multi-dimensional force sensors, joint torque sensors, and robot force control technology. | $14.7M | Series C | Apr 14, 2026 |  |
| Spirit AI | Spirit AI develops 'Universal Brains' for robotics, specializing in general-purpose embodied models that bridge the gap between simulation and real-world deployment. These models provide robots with robust generalization and precise physical interaction capabilities across diverse environments. Technical efficacy is validated by theSpirit Series (notably Spirit v1.5), which currently leads the RoboChallenge global benchmarks. Through rigorous R&D, Spirit AI aims to integrate versatile robotic companions into the modern workforce, advancing the era of embodied AI. | $145.4M | Series A | Apr 07, 2026 |  |
| Tauren | Tauren is a domestic and hybrid design enterprise of analog and analog-digital chips. At present, the company has won the recognition of the top first-line customers and the strong support of the first-line investment institutions; in the future, it will continue to cultivate the analog and analog-digital hybrid design track, and provide highlycompetitive standardized products for the market landing demand. Provide customers with stable and first-class quality semiconductor products. |  | Series E | Jan 21, 2026 |  |
| Guangxing Technology | Guangxing Technology is a die-casting mold manufacturer specializing in engine blocks, transmission housings, flywheel housings, clutches, gearboxes, and other products used in ladders, automobiles, motorcycles, and other industries. |  | Venture - Series Unknown | Nov 24, 2023 |  |
| Uds China | Uds China is an enterprise that adopts digitalization as a business transformation strategy, they need a unified approach to the full suite of processes within the organization. | $21M | Series A | Jun 07, 2023 |  |
| Singlera | Singlera is a medical firm that is working to overcome the delay in early diagnosis of cancer through screening and auxiliary. | $44.9M | Series B | Jun 08, 2022 |  |
| GenomePrecision | Genomeprecision is a molecular diagnostic enterprise integrating R&D, production and sales. It has established “real-time fluorescent quantitative PCR”, “first-generation Sanger sequencing”, “second-generation high-throughput NGS sequencing” and “capillary electrophoresis”. "Fragment Analysis" and "Chemiluminescence CLIA"five molecular diagnostic technology platforms, we will be based on clinical diagnosis and treatment needs to develop molecular diagnostic products based on the above technology platform. | $30.7M | Series C | Apr 19, 2021 |  |
| Synlight Crystal | Synlight Crystal achieves mass production of the 3rd generation semiconductor material SiC single crystal substrate. |  | Series C | Jan 21, 2021 |  |
| Sinopharm Online | Sinopharm Online has a pharmaceutical retail platform to provide users with online medication consultation, medical and health management consulting services, etc. The main sales cover Chinese and Western medicines and health products. , medical equipment, Chinese medicine | $42.5M | Series B | Apr 26, 2019 |  |

9 of 9 investments shown.

## Co-investors
- [Agibot](https://shizune.co/investors/profile/agibot) — VC Fund, 1 deal together
- Ample Harvest Finance — VC Fund, 1 deal together
- Baishide — VC Fund, 1 deal together
- [CICC Capital](https://shizune.co/investors/profile/cicc-capital) — VC Fund, 1 deal together
- [CPE](https://shizune.co/investors/profile/citic-pe) — VC Fund, 1 deal together
- [Cowin Capital](https://shizune.co/investors/profile/cowin-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Galaxy Yuanhui Investment invest in?

Galaxy Yuanhui Investment invests primarily in Industrial, Health Diagnostics and Industrial Manufacturing startups, most often at Series C and Series A stage. Most of the 9 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Galaxy Yuanhui Investment last invest?

The most recent investment recorded for Galaxy Yuanhui Investment closed in Apr 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co